← Back to Screener
Tandem Diabetes Care, Inc. (TNDM)
Price$19.34
Value ScoreD
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-15.87%
Price vs S&P 500 (4W)24.94%
VGM Score43.82
Market Capitalization$1.33B
All Metrics
Book Value / Share (Quarterly)$1.93
P/TBV (Annual)10.39x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)8.19%
Cash Flow / Share (Quarterly)$-0.05
Price vs S&P 500 (YTD)-20.17%
Gross Margin (TTM)54.93%
Net Profit Margin (TTM)-9.20%
EPS (TTM)$-1.40
10-Day Avg Trading Volume2.88M
EPS Excl Extra (TTM)$-1.40
Revenue Growth (5Y)15.26%
EPS (Annual)$-3.04
ROI (Annual)-43.55%
Gross Margin (Annual)53.81%
Net Profit Margin (5Y Avg)-13.95%
Cash / Share (Quarterly)$8.32
Revenue Growth QoQ (YoY)5.46%
ROA (Last FY)-23.23%
Revenue Growth TTM (YoY)4.54%
EBITD / Share (TTM)$-0.97
ROE (5Y Avg)-51.46%
Operating Margin (TTM)-8.16%
Cash Flow / Share (Annual)$-0.43
P/B Ratio10.01x
P/B Ratio (Quarterly)9.92x
Net Income / Employee (Annual)$-81,900
EV / Revenue (TTM)1.71x
Net Interest Coverage (TTM)-14.39x
ROA (TTM)-9.99%
EV / EBITDA (TTM)250.39x
EPS Incl Extra (Annual)$-3.04
Current Ratio (Annual)2.55x
Quick Ratio (Quarterly)2.87x
3-Month Avg Trading Volume2.33M
52-Week Price Return-6.39%
Revenue / Employee (TTM)$411,000
Tangible BV / Share (Quarterly)$2.10
P/S Ratio (Annual)1.31x
Asset Turnover (Annual)1.15x
52-Week High$29.65
Operating Margin (5Y Avg)-13.73%
EPS Excl Extra (Annual)$-3.04
CapEx CAGR (5Y)-9.19%
Tangible BV CAGR (5Y)-16.69%
26-Week Price Return-7.95%
Quick Ratio (Annual)1.89x
13-Week Price Return-14.54%
Total Debt / Equity (Annual)2.03x
Current Ratio (Quarterly)3.58x
Enterprise Value$1.75B
Revenue / Share Growth (5Y)13.02%
Asset Turnover (TTM)1.09x
Book Value / Share Growth (5Y)-17.32%
Revenue / Employee (Annual)$405,900
Inventory Turnover (Annual)3.37x
Pretax Margin (Annual)-19.74%
Cash / Share (Annual)$4.29
3-Month Return Std Dev81.91%
Gross Margin (5Y Avg)52.03%
Net Income / Employee (TTM)$-37,800
EBITDA Interim CAGR (5Y)-10.36%
ROE (Last FY)-131.93%
Net Interest Coverage (Annual)-5.88x
EPS Basic Excl Extra (Annual)$-3.04
P/FCF (TTM)109.88x
Receivables Turnover (TTM)7.69x
Total Debt / Equity (Quarterly)4.58x
EPS Incl Extra (TTM)$-1.40
Receivables Turnover (Annual)7.25x
ROI (TTM)-17.98%
P/S Ratio (TTM)1.29x
Pretax Margin (5Y Avg)-13.66%
Revenue / Share (Annual)$15.08
Tangible BV / Share (Annual)$2.10
Price vs S&P 500 (52W)-30.75%
Year-to-Date Return-12.01%
5-Day Price Return1.15%
EPS Normalized (Annual)$-3.04
ROA (5Y Avg)-12.76%
Net Profit Margin (Annual)-20.17%
Month-to-Date Return12.44%
Cash Flow / Share (TTM)$-2.98
EBITD / Share (Annual)$-2.52
Operating Margin (Annual)-18.45%
LT Debt / Equity (Annual)2.03x
P/CF (TTM)67.58x
ROI (5Y Avg)-21.38%
LT Debt / Equity (Quarterly)4.58x
EPS Basic Excl Extra (TTM)$-1.40
P/TBV (Quarterly)10.39x
P/B Ratio (Annual)9.60x
Inventory Turnover (TTM)3.46x
Pretax Margin (TTM)-9.54%
Book Value / Share (Annual)$2.27
Price vs S&P 500 (13W)-22.79%
Beta1.48x
P/FCF (Annual)176.71x
Revenue / Share (TTM)$15.02
ROE (TTM)-68.29%
52-Week Low$9.98
vGradeD
gGradeC
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.30est. -0.45
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.63
3.70
3.79
3.79
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TNDMTandem Diabetes Care, Inc. | D | C | C | $19.34 |
| SYKStryker Corporation | C | C | C | $305.66 |
| MMM3M Company | C | F | C | $153.76 |
| BSXBoston Scientific Corp. | C | B | D | $48.55 |
| MDLNMedline Inc. Class A common stock | C | D | D | $33.61 |
| BDXBecton, Dickinson and Co. | B | C | C | $151.16 |
| RMDResMed Inc. | C | B | C | $196.04 |
| DXCMDexCom, Inc. | C | B | C | $72.86 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $314.50 |
| SOLVSolventum Corporation | C | D | B | $81.01 |
| PENPenumbra, Inc. | F | C | B | $320.53 |
About
Tandem Diabetes designs and manufactures insulin pumps and related disposables for diabetes management. Since entering the market in 2012, the company has built a portfolio including its flagship t:slim X2 device and recently launched Mobi pump, with tubeless options (Tobi and Sigi) in development. Pumps account for approximately half of revenue, with disposable infusion sets representing one-third of sales. The company derives roughly 75% of revenue from the US market, with the remainder from other developed nations.